Krsnaa Diagnostics

Government Delays And Cost Pressures Will Challenge Diagnostics Optimistically

AnalystLowTarget

Not Invested

Community Contributor

Published

24 Aug 25

Updated

13 Dec 25

n/a

AnalystLowTarget's Fair Value

n/a

-20.5%

-2.0%

-20.5%

-2.0%

You can edit this narrative until Dec 14 10:05 PM. Then, changes will post as Updates.

Author's Valuation

₹803.58.4% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 13 Dec 25

Fair value Decreased 15%

KRSNAA: Board Actions And Stable Margins Will Shape A Measured Outlook

Narrative Update Analysts have trimmed their price target on Krsnaa Diagnostics from ₹949 to ₹803.5, reflecting a more conservative valuation multiple, even as forecasts for revenue growth and profit margins remain broadly resilient. What's in the News Board meeting scheduled for November 7, 2025, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).

AnalystLowTarget Fair Value

₹803.5

8.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

25.96%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.76%

Calculation

₹2.19b

Earnings '28

16.81x

PE Ratio '28

₹36.86b

Market Cap '28

₹36.86b

Market Cap '28

32.87m

No. shares '28

₹1.12k

Share Price '28

₹1.12k Share Price '28

Discounted to 2025 @ 12.76% p.a.

₹782.15

Fair Value '25